SCHEMBL14480959

SCHEMBL14480959

Cc1c(F)ccc2cc([C@H](C)Nc3ncnc4cccnc34)c(N3CCN(CC(N)=O)CC3)nc12

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.37
PIK3R2 O00459 1/20 0.35
EGFR P00533 2/20 0.35
AKT1 P31749 5/20 0.34
PARP1 P09874 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
SOS1 Q07889 2/20 0.34
RPS6KB1 P23443 3/20 0.33
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
ERBB2 P04626 1/20 0.33
CYP3A4 P08684 1/20 0.33
ABCC1 P33527 1/20 0.33
GPR6 P46095 1/20 0.33
OPRK1 P41145 2/20 0.33
AURKB Q96GD4 1/20 0.33
INCENP Q9NQS7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14481018 0.93 TNF (0.38) PIK3CDPIK3R2CD274SOS1GPR6
SCHEMBL14480679 0.92 PIK3CD (0.36) PIK3CDPIK3R2EGFRCD274ERBB2
SCHEMBL15900051 0.90 PIK3CD (0.38) PIK3CDPIK3R2AKT1PARP1CD274
SCHEMBL14481337 0.90 PIK3CD (0.38) PIK3CDPIK3R2AKT1PARP1CD274
SCHEMBL15899858 0.88 PIK3CD (0.38) PIK3CDPIK3R2EGFRAKT1PARP1
SCHEMBL14480930 0.88 PIK3CD (0.39) PIK3CDPIK3R2AKT1CD274SOS1
SCHEMBL14480929 0.88 PIK3CD (0.39) PIK3CDPIK3R2AKT1CD274SOS1
SCHEMBL14480909 0.87 PIK3CD (0.37) PIK3CDPIK3R2AKT1PARP1CD274
SCHEMBL14480910 0.87 PIK3CD (0.37) PIK3CDPIK3R2AKT1PARP1CD274
SCHEMBL15899977 0.87 PIK3CD (0.37) PIK3CDPIK3R2CD274OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2499129-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-07-30 EP claimed
US-8653105-B2 Quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2014-02-18 US claimed
EP-2499129-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-07-30 EP disclosed
US-8653105-B2 Quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2014-02-18 US disclosed
US-20130012517-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2013-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012517-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors PDXK, MAP2K2, PDPK1 PIK3CD 13/4885PIK3R2 106/4885EGFR 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.